Related Experiment Video

Updated: May 25, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Emerging role of microRNAs in drug-resistant breast cancer

Sarmila Majumder1, Samson T Jacob

  • 1Department of Molecular and Cellular Biochemistry, College of Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. Sarmila.Majumder@osumc.edu

Gene Expression
|January 25, 2012
PubMed

Insights

Drug resistance in cancer is a major hurdle. This review explores how microRNAs (miRNAs), small noncoding RNAs, regulate and contribute to therapeutic resistance, offering potential new targets for treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Therapeutic resistance is a significant challenge in cancer treatment.
  • Breast cancer drug resistance involves complex mechanisms.
  • Small noncoding RNAs, specifically microRNAs (miRNAs), are increasingly recognized for their regulatory roles.

Purpose of the Study:

  • To review the altered miRNA profiles associated with drug resistance development.
  • To discuss the critical role of miRNAs in conferring resistance to cancer therapeutics.
  • To highlight the potential of miRNAs as biomarkers and therapeutic targets.

Main Methods:

  • Literature review of studies on miRNA and cancer drug resistance.
  • Analysis of research detailing miRNA expression changes in resistant cancer models.
  • Synthesis of findings on miRNA-mediated mechanisms of resistance.

Main Results:

  • miRNA expression profiles are significantly altered during the development of drug resistance.
  • miRNAs play a critical regulatory role in mediating resistance to various therapeutic agents.
  • Specific miRNAs are implicated in conferring resistance across different cancer types, including breast cancer.

Conclusions:

  • Dysregulated miRNAs are key players in cancer therapeutic resistance.
  • Identifying differentially expressed miRNAs can aid in developing prognostic and predictive markers.
  • Targeting specific miRNAs presents a promising strategy for overcoming drug resistance in cancer therapy.

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...